$KRRO
Korro Bio, Inc.

2021 Q4 Form 10-Q Financial Statement

#000095017021004466 Filed on November 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $0.00 $0.00 $11.25M
YoY Change -100.0% -100.0% -53.6%
Cost Of Revenue $0.00
YoY Change -100.0%
Gross Profit $11.25M
YoY Change 36.53%
Gross Profit Margin 100.03%
Selling, General & Admin $8.605M $9.328M $6.510M
YoY Change 2.44% 43.29% 52.46%
% of Gross Profit 57.87%
Research & Development $12.75M $15.66M $10.15M
YoY Change 7.81% 54.26% 94.46%
% of Gross Profit 90.25%
Depreciation & Amortization $737.0K $735.0K $301.0K
YoY Change 88.97% 144.19% 40.0%
% of Gross Profit 2.68%
Operating Expenses $21.36M $24.99M $16.67M
YoY Change 5.58% 49.95% -34.62%
Operating Profit -$24.99M -$5.418M
YoY Change 361.24% 332.75%
Interest Expense -$100.0K $182.0K $90.00K
YoY Change -600.0% 102.22% -86.76%
% of Operating Profit
Other Income/Expense, Net -$39.00K -$139.0K
YoY Change
Pretax Income -$21.50M -$25.15M -$5.326M
YoY Change 109.53% 372.25% 826.26%
Income Tax $2.000K $3.000K $15.00K
% Of Pretax Income
Net Earnings -$21.50M -$25.16M -$5.341M
YoY Change 110.13% 370.98% 828.87%
Net Earnings / Revenue -47.49%
Basic Earnings Per Share
Diluted Earnings Per Share -$621.4K -$730.2K -$161.5K
COMMON SHARES
Basic Shares Outstanding 34.60M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $130.7M $148.1M $226.0M
YoY Change -40.67% -34.49% 36.75%
Cash & Equivalents $79.64M $112.0M $226.0M
Short-Term Investments $51.07M $36.04M $0.00
Other Short-Term Assets $185.0K $1.835M $3.100M
YoY Change 81.37% -40.81% 909.77%
Inventory
Prepaid Expenses
Receivables $144.0K
Other Receivables $0.00
Total Short-Term Assets $134.7M $149.9M $227.3M
YoY Change -40.13% -34.05% 36.35%
LONG-TERM ASSETS
Property, Plant & Equipment $5.522M $6.232M $5.200M
YoY Change -24.22% 19.85% 232.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $11.72M $12.40M
YoY Change
Other Assets $2.019M $1.726M $1.800M
YoY Change 12.17% -4.11% 1682.18%
Total Long-Term Assets $50.61M $52.28M $7.020M
YoY Change 27.62% 644.67% 71.22%
TOTAL ASSETS
Total Short-Term Assets $134.7M $149.9M $227.3M
Total Long-Term Assets $50.61M $52.28M $7.020M
Total Assets $185.4M $202.2M $234.3M
YoY Change -29.98% -13.71% 37.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.748M $3.607M $4.089M
YoY Change -50.09% -11.79% 13.58%
Accrued Expenses $6.101M $5.197M $4.380M
YoY Change -8.43% 18.65% -77.07%
Deferred Revenue $24.02M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $833.0K
YoY Change
Total Short-Term Liabilities $11.43M $10.49M $32.92M
YoY Change -57.09% -68.15% -54.41%
LONG-TERM LIABILITIES
Long-Term Debt $14.17M $15.00M $0.00
YoY Change -5.55% -100.0%
Other Long-Term Liabilities $87.00K $278.0K $1.800M
YoY Change -99.72% -84.56% -72.73%
Total Long-Term Liabilities $87.00K $278.0K $1.800M
YoY Change -99.81% -84.56% 710.81%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.43M $10.49M $32.92M
Total Long-Term Liabilities $87.00K $278.0K $1.800M
Total Liabilities $54.53M $55.07M $34.73M
YoY Change -24.5% 58.57% -57.96%
SHAREHOLDERS EQUITY
Retained Earnings -$180.1M -$158.6M -$85.17M
YoY Change 88.77% 86.2% 34.43%
Common Stock $35.00K $35.00K $34.00K
YoY Change 2.94% 2.94% -99.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $130.8M $147.1M $199.6M
YoY Change
Total Liabilities & Shareholders Equity $185.4M $202.2M $234.3M
YoY Change -29.98% -13.71% 37.15%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$21.50M -$25.16M -$5.341M
YoY Change 110.13% 370.98% 828.87%
Depreciation, Depletion And Amortization $737.0K $735.0K $301.0K
YoY Change 88.97% 144.19% 40.0%
Cash From Operating Activities -$17.89M -$15.02M -$10.73M
YoY Change 20.62% 40.01% -114.39%
INVESTING ACTIVITIES
Capital Expenditures -$61.00K -$311.0K -$1.000M
YoY Change -98.62% -68.9% 566.67%
Acquisitions
YoY Change
Other Investing Activities -$14.59M -$8.103M -$20.00K
YoY Change 72830.0% 40415.0% -100.42%
Cash From Investing Activities -$14.65M -$8.414M -$1.010M
YoY Change 229.89% 733.07% -121.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 109.0K 349.0K 40.61M
YoY Change -99.29% -99.14% -31.62%
NET CHANGE
Cash From Operating Activities -17.89M -15.02M -10.73M
Cash From Investing Activities -14.65M -8.414M -1.010M
Cash From Financing Activities 109.0K 349.0K 40.61M
Net Change In Cash -32.43M -23.09M 28.87M
YoY Change 733.57% -179.97% -79.17%
FREE CASH FLOW
Cash From Operating Activities -$17.89M -$15.02M -$10.73M
Capital Expenditures -$61.00K -$311.0K -$1.000M
Free Cash Flow -$17.83M -$14.71M -$9.730M
YoY Change 71.25% 51.2% -113.02%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2014-11-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001703647
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34602285
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112034000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
220341000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
36040000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1835000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4723000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1820000
CY2021Q3 us-gaap Assets
Assets
202185000
CY2020Q4 us-gaap Assets
Assets
264722000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3607000
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
Lexington
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5506000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5197000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6663000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
14068000
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02421
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
315-4600
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
FREQ
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39062
dei Entity Registrant Name
EntityRegistrantName
FREQUENCY THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2324450
dei Entity Address Address Line1
EntityAddressAddressLine1
75 Hayden Avenue
CY2021Q3 us-gaap Assets Current
AssetsCurrent
149909000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
225064000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
12397000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6232000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7287000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
31921000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
30551000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1726000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33964000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1681000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
397000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
10485000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26634000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
29306000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30597000
CY2021Q3 us-gaap Long Term Loans From Bank
LongTermLoansFromBank
15000000
CY2020Q4 us-gaap Long Term Loans From Bank
LongTermLoansFromBank
15000000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
278000
CY2021Q3 us-gaap Liabilities
Liabilities
55069000
CY2020Q4 us-gaap Liabilities
Liabilities
72231000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34551875
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34551875
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33964000
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
35000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
34000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
305663000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
287829000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
27000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-158585000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-95399000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
147116000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
192491000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
202185000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
264722000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11247000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14068000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27034000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15662000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10153000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48169000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25587000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9328000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6512000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28571000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18720000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
24990000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
16665000
us-gaap Operating Expenses
OperatingExpenses
76740000
us-gaap Operating Expenses
OperatingExpenses
44307000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-24990000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5418000
us-gaap Operating Income Loss
OperatingIncomeLoss
-62672000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17273000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
172000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
74000
us-gaap Investment Income Interest
InvestmentIncomeInterest
315000
us-gaap Investment Income Interest
InvestmentIncomeInterest
962000
CY2021Q3 us-gaap Interest Expense
InterestExpense
182000
us-gaap Interest Expense
InterestExpense
582000
CY2021Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-9000
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-23000
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
65000
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-4000
CY2020Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
18000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
16000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
27000
CY2021Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
139000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
227000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25152000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5326000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-63173000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16219000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
60000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-25155000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-5341000
us-gaap Net Income Loss
NetIncomeLoss
-63186000
us-gaap Net Income Loss
NetIncomeLoss
-16279000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.73
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.84
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34448746
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33073889
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34268736
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31729702
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-25155000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-5341000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-16000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1188000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-24000
us-gaap Net Income Loss
NetIncomeLoss
-63186000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
147116000
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
161701000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2643000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
462000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
40143000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-16000
us-gaap Net Income Loss
NetIncomeLoss
-63186000
us-gaap Net Income Loss
NetIncomeLoss
-16279000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-24000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-4000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-16000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-24000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-10000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25159000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5357000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-63210000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16289000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
167358000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7218000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1162000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
40143000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-10000
us-gaap Net Income Loss
NetIncomeLoss
-16279000
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
199592000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
192491000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16586000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
61000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-5341000
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
199592000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
166040000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5886000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
61000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
288000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-25155000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
147116000
us-gaap Profit Loss
ProfitLoss
-63186000
us-gaap Profit Loss
ProfitLoss
-16279000
us-gaap Share Based Compensation
ShareBasedCompensation
16586000
us-gaap Share Based Compensation
ShareBasedCompensation
7218000
us-gaap Depreciation
Depreciation
2038000
us-gaap Depreciation
Depreciation
760000
freq Non Cash Lease Expenses
NonCashLeaseExpenses
495000
freq Non Cash Lease Expenses
NonCashLeaseExpenses
256000
us-gaap Paid In Kind Interest
PaidInKindInterest
179000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-16000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2888000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-985000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1910000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2870000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-14068000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-27034000
freq Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-7000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1202000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
869000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-58171000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30355000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2853000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2253000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
66226000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
17600000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
17090000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-51479000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14837000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1188000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1162000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
61000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
40143000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1249000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
41305000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-108401000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
25787000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
222161000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
200259000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
113760000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
226046000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2163000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
34000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
24000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3522000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5062000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
666000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
647000
CY2021Q3 freq Accrued Third Party Research And Development Expenses Current
AccruedThirdPartyResearchAndDevelopmentExpensesCurrent
766000
CY2020Q4 freq Accrued Third Party Research And Development Expenses Current
AccruedThirdPartyResearchAndDevelopmentExpensesCurrent
874000
CY2021Q3 freq Accrued Income Taxes And Other Accrued Liabilities Current
AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent
243000
CY2020Q4 freq Accrued Income Taxes And Other Accrued Liabilities Current
AccruedIncomeTaxesAndOtherAccruedLiabilitiesCurrent
80000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5197000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6663000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9679000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10499000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3447000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3212000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6232000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7287000
CY2021Q3 us-gaap Depreciation
Depreciation
735000
us-gaap Depreciation
Depreciation
2038000
CY2020Q3 us-gaap Depreciation
Depreciation
301000
us-gaap Depreciation
Depreciation
760000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6757125
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34551875
us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.0475
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-25155000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-5341000
us-gaap Net Income Loss
NetIncomeLoss
-63186000
us-gaap Net Income Loss
NetIncomeLoss
-16279000
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34448746
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33073889
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34268736
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31729702
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.73
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.84
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7977699
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7977699
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6757125
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8292721
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
12231000
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2406000
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34551875
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33964000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33964000
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8370005
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.005
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.798
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.64
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
22.57
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.02
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
15.73
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3418000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
5751000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5886000
us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
0
CY2021Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2021Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2643000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16586000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7218000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
46901000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M20D
CY2021Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
0
CY2020 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
600000

Files In Submission

Name View Source Status
0000950170-21-004466-index-headers.html Edgar Link pending
0000950170-21-004466-index.html Edgar Link pending
0000950170-21-004466.txt Edgar Link pending
0000950170-21-004466-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
freq-20210930.htm Edgar Link pending
freq-20210930.xsd Edgar Link pending
freq-20210930_cal.xml Edgar Link unprocessable
freq-20210930_def.xml Edgar Link unprocessable
freq-20210930_htm.xml Edgar Link completed
freq-20210930_lab.xml Edgar Link unprocessable
freq-20210930_pre.xml Edgar Link unprocessable
freq-ex31_1.htm Edgar Link pending
freq-ex31_2.htm Edgar Link pending
freq-ex32_1.htm Edgar Link pending
freq-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending